Icotrokinra

Icotrokinra is an investigational oral peptide drug used to treat moderate-to-severe plaque psoriasis, with potential for other inflammatory diseases like ulcerative colitis and psoriatic arthritis. It works by blocking the IL-23 receptor, which plays a role in these inflammatory conditions. Clinical trials have shown it to be effective for clearing skin, even in hard-to-treat areas like the scalp and genitals, and it is being studied as a next-generation alternative to injectable biologics. It is grouped under the following drug class(es): Interleukin Inhibitors. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Glycinamide, N-acetyl-3-mercapto-L-valyl-L-asparaginyl-L-threonyl-7-methyl-L-tryptophyl-N6-acetyl-L-lysyl-3-mercapto-L-valyl-O-(2-aminoethyl)-L-tyrosyl-3-(2-naphthalenyl)-L-alanyl-4-aminotetrahydro-2H-pyran-4-carbonyl-L-alpha-glutamyl-L-asparaginyl-3-(3-pyridinyl)-L-alanyl-N2-methyl- and cyclic (1–>6)-disulfide. Its PubChem CID is 162462321.

CAS No 2763602-16-8
Molecular Formula C90H120N20O22S2
Molecular Weight 1898.2 g/mol
Synonyms (4S)-4-[[4-[[(2S)-2-[[(2S)-2-[[(4R,7S,10S,13S,16S,19R)-19-acetamido-7-(4-acetamidobutyl)-16-(2-amino-2-oxoethyl)-13-[(1R)-1-hydroxyethyl]-3,3,20,20-tetramethyl-10-[(7-methyl-1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-[4-(2-aminoethoxy)phenyl]propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]oxane-4-carbonyl]amino]-5-[[(2S)-4-amino-1-[[(2S)-1-[(2-amino-2-oxoethyl)-methylamino]-1-oxo-3-pyridin-3-ylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid

Frequently Asked Questions